Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus with worldwide distribution. Primary infection with EBV occurs early in life and typically presents as infectious mononucleosis. The usual course of the disease is benign and most patients recover uneventfully. Severe infections are reported particularly in immunocompromised patients. Mild, asymptomatic pneumonitis is reported in about 5–10% of cases of infectious mononucleosis, but severe pneumonitis with hypoxemia is very rare in immunocompetent individuals. We report a young female adolescent in whom an acute EBV infection led to severe bilateral pneumonitis, a systemic inflammatory response and intracerebral bleeding. The clinical course and results of quantitative viral DNA determinations in plasma are presented.

Keywords:
Epstein-Barr virus infection, Acute respiratory failure, Pneumonitis, Quantitative PCR
1.
Cohen JI: Epstein-Barr virus infection. N Engl J Med 2000;343:481–492.
2.
Jenson HB: Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr 2000;12:263–268.
3.
Haller A, von Segesser L, Baumann PC, Krause M: Severe respiratory insufficiency complicating Epstein-Barr virus infection: Case report and review. Clin Infect Dis 1995;21:206–209.
4.
Kikuta H, Sakiyama Y, Matsumoto S, Oh-Ishi T, Nakano T, Nagashima T, Oka T, Hironaka T, Hirai K: Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood 1993;82:3259–3264.
5.
Collins M, Fleisher G, Kreisberg J, Fager S: Role of steroids in the treatment of infectious mononucleosis in the ambulatory college student. J Am Coll Health 1984;33:101–105.
6.
Torre D, Tambini R: Acyclovir for treatment of infectious mononucleosis: A meta-analysis. Scand J Infect Dis 1999;31:543–547.
7.
Andersson J, Ernberg I: Management of Epstein-Barr virus infections. Am J Med 1988;85(suppl 2A):107–115.
8.
Okano M, Gross TG: Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol 1996;53:111–115.
9.
Berger C, Day P, Meier G, Zingg W, Bossard W, Nadal D: Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. J Med Virol 2001;64:505–512.
10.
Van Laar JAM, Buysse CMP, Vossen ACTM, Hjalmarsson B, van Lom K, Deinum J: Epstein-Barr viral load assessment in immunocompetent patients with fulminant infectious mononucleosis. Arch Intern Med 2002;162:837–839.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.